This report provides a summary of the good practice hepatitis C roadshow held by HCV Action and Public Health England in Cambridge on 9th May 2017. The roadshow was aimed at sharing good practice around hepatitis C and instigating local action to address the virus. The report includes summaries of the talks and workshops held on the day, as well as attendees' pledges for taking further action on hepatitis C.
Access and Uptake of Direct Acting Antiviral Medicines in the UK and selected European countries
This report, produced by IMS Health and commissioned by the Association of the British Pharmaceutical Industry (ABPI), provides information related to the uptake of Direct Acting Antiviral treatments (DAAs) over the last five years, to June 2016. The intention of the report is to benchmark the UK – in relation to patient access to these medicines – compared with other European countries. It finds that there have been significant variances in the ability of patients to access these medicines. For example, Portugal, Belgium and Germany have now treated over a quarter of their estimated prevalent patients. By contrast, the trend in the UK has been one of slower and lower levels of access.